US 11,058,677

Application 14/650,955 · Granted Jul 13, 2021

Lfa-1 inhibitor formulations

Estimated expiration

December 18, 2033

7y 29d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Dec 18, 2013
+ 20 years
Dec 18, 2033
PTA +0d
Dec 18, 2033
No TD
—
Final
Dec 18, 2033

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
June 10, 2015
Earliest effective filing
December 18, 2013
Issue date
July 13, 2021
PTA
0 days
Base expiry (before PTA)
December 18, 2033

December 18, 2013 + 20 years = December 18, 2033

  • National stage entry of application PCTUS2013076041, filed Dec 18, 2013
  • PRO61/758,147 — Provisional — not used for base term
  • PRO61/739,609 — Provisional — not used for base term
  • PRO61/739,609 — Provisional — not used for base term
  • PRO61/758,147 — Provisional — not used for base term

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 14/650,955 · US 11,058,677

PatentReply compiles the prosecution history behind US 11,058,677: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US11058677

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.